dc.contributor.author | Lee, JY | |
dc.contributor.author | Cutts, RJ | |
dc.contributor.author | White, I | |
dc.contributor.author | Augustin, Y | |
dc.contributor.author | Garcia-Murillas, I | |
dc.contributor.author | Fenwick, K | |
dc.contributor.author | Matthews, N | |
dc.contributor.author | Turner, NC | |
dc.contributor.author | Harrington, K | |
dc.contributor.author | Gilbert, DC | |
dc.contributor.author | Bhide, S | |
dc.date.accessioned | 2020-05-26T11:23:54Z | |
dc.date.issued | 2020-04-17 | |
dc.identifier.citation | Frontiers in oncology, 2020, 10 pp. 505 - ? | |
dc.identifier.issn | 2234-943X | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/3635 | |
dc.identifier.eissn | 2234-943X | |
dc.identifier.doi | 10.3389/fonc.2020.00505 | |
dc.description.abstract | Background: Following chemo-radiotherapy (CRT) for human papilloma virus positive (HPV+) anal squamous cell carcinoma (ASCC), detection of residual/recurrent disease is challenging. Patients frequently undergo unnecessary repeated biopsies for abnormal MRI/clinical findings. In a pilot study we assessed the role of circulating HPV-DNA in identifying "true" residual disease. Methods: We prospectively collected plasma samples at baseline (n = 21) and 12 weeks post-CRT (n = 17). Circulating HPV-DNA (cHPV DNA) was measured using a novel next generation sequencing (NGS) assay, panHPV-detect, comprising of two primer pools covering distinct regions of eight high-risk HPV genomes (16, 18, 31, 33, 35, 45, 52, and 58) to detect circulating HPV-DNA (cHPV DNA). cHPV-DNA levels post-CRT were correlated to disease response. Results: In pre-CRT samples, panHPV-detect demonstrated 100% sensitivity and specificity for HPV associated ASCC. PanHPV-detect was able to demonstrate cHPV-DNA in 100% (9/9) patients with T1/T2N0 cancers. cHPV-DNA was detectable 12 weeks post CRT in just 2/17 patients, both of whom relapsed. 1/16 patients who had a clinical complete response (CR) at 3 months post-CRT but relapsed at 9 months and 1/1 patient with a partial response (PR). PanHPV-detect demonstrated 100% sensitivity and specificity in predicting response to CRT. Conclusion: We demonstrate that panHPV-detect, an NSG assay is a highly sensitive and specific test for the identification of cHPV-DNA in plasma at diagnosis. cHPV-DNA post-treatment may predict clinical response to CRT. | |
dc.format | Electronic-eCollection | |
dc.format.extent | 505 - ? | |
dc.language | eng | |
dc.language.iso | eng | |
dc.publisher | FRONTIERS MEDIA SA | |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0 | |
dc.title | Next Generation Sequencing Assay for Detection of Circulating HPV DNA (cHPV-DNA) in Patients Undergoing Radical (Chemo)Radiotherapy in Anal Squamous Cell Carcinoma (ASCC). | |
dc.type | Journal Article | |
dcterms.dateAccepted | 2020-03-20 | |
rioxxterms.versionofrecord | 10.3389/fonc.2020.00505 | |
rioxxterms.licenseref.uri | https://creativecommons.org/licenses/by/4.0 | |
rioxxterms.licenseref.startdate | 2020-01 | |
rioxxterms.type | Journal Article/Review | |
dc.relation.isPartOf | Frontiers in oncology | |
pubs.notes | Not known | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Breast Cancer Research | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Breast Cancer Research/Molecular Oncology | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Breast Cancer Research | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Breast Cancer Research/Molecular Oncology | |
pubs.publication-status | Published | |
pubs.volume | 10 | |
pubs.embargo.terms | Not known | |
icr.researchteam | Molecular Oncology | |
dc.contributor.icrauthor | Cutts, Rosalind | |
dc.contributor.icrauthor | White, Ingrid | |
dc.contributor.icrauthor | Garcia-Murillas, Isaac | |
dc.contributor.icrauthor | Turner, Nicholas | |
dc.contributor.icrauthor | Harrington, Kevin | |